A phase II study of the HDAC inhibitor SB939 in patients with castration resistant prostate cancer: NCIC clinical trials group study IND195

Investigational New Drugs

Volumn 33, Issue 4, 2015, Pages 969-976

  Eigl, B J ^a   North, S ^b   Winquist, E ^c   Finch, D ^a   Wood, L ^d   Sridhar, S S ^e   Powers, J ^f   Good, J ^g   Sharma, M ^h   Squire, J A ^g   Bazov, J ^h   Jamaspishvili, T ^g   Cox, M E ^h   Bradbury, P A ^f   Eisenhauer, E A ^f   Chi, K N ^a  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b CROSS CANCER INSTITUTE   (Canada)

^c LONDON HEALTH SCIENCES CENTRE   (Canada)

^d QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

^e PRINCESS MARGARET HOSPITAL   (Canada)

^f Queen's Cancer Research Institute   (Canada)

^g QUEEN S UNIVERSITY   (Canada)

^h VANCOUVER PROSTATE CENTRE   (Canada)

Author keywords

Castration resistant prostate cancer; HDAC; Histone deacetylase inhibitors

Indexed keywords

ANDROGEN RECEPTOR; HISTONE DEACETYLASE INHIBITOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROSTATE SPECIFIC ANTIGEN; SB 939; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BENZIMIDAZOLE DERIVATIVE; ERG PROTEIN, HUMAN; KALLIKREIN; KALLIKREIN-RELATED PEPTIDASE 3, HUMAN; PTEN PROTEIN, HUMAN; SB939 COMPOUND; SERINE PROTEINASE; TMPRSS2 PROTEIN, HUMAN; TRANSACTIVATOR PROTEIN;

ADULT; AGED; ANOREXIA; ARTICLE; CASTRATION RESISTANT PROSTATE CANCER; CELL PROLIFERATION; CIRCULATING TUMOR CELL; CONTROLLED STUDY; DISEASE COURSE; DISEASE DURATION; DNA MODIFICATION; DRUG DOSE REDUCTION; DRUG TOLERABILITY; DYSPNEA; EPIGENETICS; FATIGUE; HEART ARREST; HEART FUNCTION; HEART INFARCTION; HUMAN; LABORATORY TEST; MONOTHERAPY; MULTICENTER STUDY; NAUSEA; OVERALL SURVIVAL; PATIENT SELECTION; PHASE 2 CLINICAL TRIAL; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; VERY ELDERLY; VOMITING; BLOOD; CLINICAL TRIAL; DISEASE FREE SURVIVAL; GENETICS; MALE; METABOLISM; MIDDLE AGED; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; TUMOR EMBOLISM;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BENZIMIDAZOLES; DISEASE-FREE SURVIVAL; HISTONE DEACETYLASE INHIBITORS; HUMANS; KALLIKREINS; MALE; MIDDLE AGED; NEOPLASTIC CELLS, CIRCULATING; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; PTEN PHOSPHOHYDROLASE; SERINE ENDOPEPTIDASES; TRANS-ACTIVATORS;

EID: 84944441620     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-015-0252-4     Document Type: Article

References (32)

1. Abbas A, Gupta S (2008) The role of histone deacetylases in prostate cancer. Epigenetics 3(6):300-309
2. Weichert W, Roske A, Gekeler V, Beckers T, Stephan C, Jung K et al (2008) Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy. Br J Cancer 98(3):604-610
3. Edwards A, Li J, Atadja P, Bhalla K, Haura EB (2007) Effect of the histone deacetylase inhibitor LBH589 against epidermal growth factor receptor-dependent human lung cancer cells. Mol Cancer Ther 6(9):2515-2524
4. Fiskus W, Ren Y, Mohapatra A, Bali P, Mandawat A, Rao R et al (2007) Hydroxamic acid analogue histone deacetylase inhibitors attenuate estrogen receptor-alpha levels and transcriptional activity: a result of hyperacetylation and inhibition of chaperone function of heat shock protein 90. Clin Cancer Res 13(16):4882-4890
5. Pratt WB, Galigniana MD, Morishima Y, Murphy PJ (2004) Role of molecular chaperones in steroid receptor action. Essays Biochem 40:41-58
6. Kantharaj E, Jayaraman R (2011) Histone deacetylase inhibitors as therapeutic agents for cancer therapy: Drug metabolism and pharmacokinetic properties. In: Rundfeldt C, (ed.). Drug development - a case study based insight into modern strategies. InTech, 101
7. Novotny-Diermayr V, Sangthongpitag K, Hu CY, Wu X, Sausgruber N, Yeo P et al (2010) SB939, a novel potent and orally active histone deacetylase inhibitor with high tumor exposure and efficacy in mouse models of colorectal cancer. Mol Cancer Ther 9(3):642-652
8. Wang H, Yu N, Chen D, Lee KC, Lye PL, Chang JW et al (2011) Discovery of (2E)-3-{2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl}-N-hydroxyacrylami de (SB939), an orally active histone deacetylase inhibitor with a superior preclinical profile. J Med Chem 54(13):4694-4720
9. Razak AR, Hotte SJ, Siu LL, Chen EX, Hirte HW, Powers J et al (2011) Phase I clinical, pharmacokinetic and pharmacodynamic study of SB939, an oral histone deacetylase (HDAC) inhibitor, in patients with advanced solid tumours. Br J Cancer 104(5):756-762
10. Yong WP, Goh BC, Soo RA, Toh HC, Ethirajulu K, Wood J et al (2011) Phase I and pharmacodynamic study of an orally administered novel inhibitor of histone deacetylases, SB939, in patients with refractory solid malignancies. Ann Oncol 22(11):2516-2522
11. Iljin K, Wolf M, Edgren H, Gupta S, Kilpinen S, Skotheim RI et al (2006) TMPRSS2 fusions with oncogenic ETS factors in prostate cancer involve unbalanced genomic rearrangements and are associated with HDAC1 and epigenetic reprogramming. Cancer Res 66(21):10242-10246
12. Squire JA (2009) TMPRSS2-ERG and PTEN loss in prostate cancer. Nat Genet 41(5):509-510
13. Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA et al (2008) Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 26(7):1148-1159
14. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228-247
15. de Bono JS, Scher HI, Montgomery RB, Parker C, Miller MC, Tissing H et al (2008) Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res 14(19):6302-6309
16. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228-247
17. Schmittgen TD, Livak KJ (2008) Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 3(6):1101-1108
18. Yoshimoto M, Joshua AM, Cunha IW, Coudry RA, Fonseca FP, Ludkovski O et al (2008) Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome. Mod Pathol 21(12):1451-1460
19. Yoshimoto M, Ludkovski O, DeGrace D, Williams JL, Evans A, Sircar K et al (2012) PTEN genomic deletions that characterize aggressive prostate cancer originate close to segmental duplications. Genes Chromosomes Cancer 51(2):149-160
20. Chaux A, Albadine R, Toubaji A, Hicks J, Meeker A, Platz EA et al (2011) Immunohistochemistry for ERG expression as a surrogate for TMPRSS2-ERG fusion detection in prostatic adenocarcinomas. Am J Surg Pathol 35(7):1014-1020
21. Lotan TL, Gurel B, Sutcliffe S, Esopi D, Liu W, Xu J et al (2011) PTEN protein loss by immunostaining: analytic validation and prognostic indicator for a high risk surgical cohort of prostate cancer patients. Clin Cancer Res 17(20):6563-6573
22. Simon R (1989) Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10(1):1-10
23. Welsbie DS, Xu J, Chen Y, Borsu L, Scher HI, Rosen N et al (2009) Histone deacetylases are required for androgen receptor function in hormone-sensitive and castrate-resistant prostate cancer. Cancer Res 69(3):958-966
24. Molife LR, Attard G, Fong PC, Karavasilis V, Reid AH, Patterson S et al (2010) Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC). Ann Oncol 21(1):109-113
25. Rathkopf DE, Picus J, Hussain A, Ellard S, Chi KN, Nydam T et al (2013) A phase 2 study of intravenous panobinostat in patients with castration-resistant prostate cancer. Cancer Chemother Pharmacol 72(3):537-544
26. Molife R, Fong P, Scurr M, Judson I, Kaye S, de Bono J (2007) HDAC inhibitors and cardiac safety. Clin Cancer Res 13(3):1068, author reply -9
27. Munster P, Marchion D, Bicaku E, Schmitt M, Lee JH, DeConti R et al (2007) Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study. J Clin Oncol 25(15):1979-1985
28. Munster PN, Marchion D, Thomas S, Egorin M, Minton S, Springett G et al (2009) Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker. Br J Cancer 101(7):1044-1050
29. Tsai SC, Valkov N, Yang WM, Gump J, Sullivan D, Seto E (2000) Histone deacetylase interacts directly with DNA topoisomerase II. Nat Genet 26(3):349-353
30. Rathkopf D, Wong BY, Ross RW, Anand A, Tanaka E, Woo MM et al (2010) A phase I study of oral panobinostat alone and in combination with docetaxel in patients with castration-resistant prostate cancer. Cancer Chemother Pharmacol 66(1):181-189
31. Wissing MD, Mendonca J, Kortenhorst MS, Kaelber NS, Gonzalez M, Kim E et al (2013) Targeting prostate cancer cell lines with polo-like kinase 1 inhibitors as a single agent and in combination with histone deacetylase inhibitors. FASEB J: Off Publ Fed Am Soc Exp Biol 27(10):4279-4293
32. Ellis L, Ku SY, Ramakrishnan S, Lasorsa E, Azabdaftari G, Godoy A, et al (2013) Combinatorial antitumor effect of HDAC and the PI3K-Akt-mTOR pathway inhibition in a Pten defecient model of prostate cancer. Oncotarget